1Lancranjan I,Bruns C,Grass P,et al.Sandostatin(r) LAR(r):a promising therapeutictool in the management of acrom-galic patients[J].Metabolim,1996,45:67.
2Freda PU, Wardlaw SL. Clinical review 110: diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab 1999;84:3859-66.
3Krieger MD, Couldwell WT, Weiss MH. Assessment of long-term remission of acromegaly following surgery. J Neurosurg 2003;98:719-24.
5Ayuk J, Stewart SE, Stewart PM, et al. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 2002;87:4142-6.
6Newman CB, Melmed S, George A, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3034-40.
7Chanson P, Boerlin V, Ajzenberg C, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.Clin Endocrinol (Oxf) 2000;53:577-86.
8Wasko R, Ruchala M, Sawicka J, et al. Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide,in acromegaly. J Endocrinol Invest 2000;23:12-8.
9Knosp E, Steiner E, Kitz K, et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993;33:610-7.
10Colao A, Ferone D, Marzullo P, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86:2779-86.
3Lancranjan I, Bruns C, Grass P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients [J]. Metabolism, 1996, 45 (8Suppl.1) !67-71:
